REFERENCES
- Adachi K, Kashii S, Masai H, et al. Mechanism of pathogenesis of glutamate neurotoxicity in retinal ischemia. Graefes Arch Clin Exp Ophthalmol 1998; 23: 766–774, [CSA]
- Buchi E R. Cell death in the rat retina after a pressure-induced ischemia reperfusion insult. An electron microscopic study: ganglion cell layer and inner nuclear layer. Exp Eye Res 1992; 55: 605–613, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Weber M, Bonaventure N, Sahel J A. Protective role of excitatory amino acid antagonists in experimental retinal ischemia. Grafes Arch Exp Ophthalmol 1995; 233: 360–365, [CSA]
- Wu S M, Maple B R. Amino acid neurotransmitters in the retina: a functional overview. Vis Res 1998; 38: 1371–1384, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bloomfield S A, Dowling J E. Roles of aspartate and glutamate in synaptic transmission in rabbit retina. I. Outer plexiform layer. J Neurophysiol 1985; 53: 699–713, [PUBMED], [INFOTRIEVE], [CSA]
- Bloomfield S A, Dowling J E. Roles of aspartate and glutamate in synaptic transmission in rabbit retina. II. Inner plexiform layer. J Neurophysiol 1985; 53: 714–725, [PUBMED], [INFOTRIEVE], [CSA]
- Osborne N N, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol 1999; 43: S102–128, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Melena J, Osborne N N. Voltage-dependent calcium channels in the rat retina: involvement in NMDA-stimulated influx of calcium. Exp Eye Res 2001; 72: 393–401, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cohn J N. Calcium, vascular smooth muscle, and calcium entry blockers in hypertension. Ann Intern Med 1983; 98: 806–809, [PUBMED], [INFOTRIEVE], [CSA]
- Hof R P. Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil, and diltiazem. Br J Pharmacol 1982; 78: 375–394, [CSA]
- Yamamoto T, Kitazawa Y. Vascular pathogenesis of normal-tension glaucoma: a possible pathogenetic factor, other than intraocular pressure, of glaucomatous optic neuropathy. Prog Retin Eye Res. 1998; 17: 127–143, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Toriu N, Sasaoka M, Shimazawa M, et al. Effect of lomerizine, a novel Ca2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits. J Ocul Pharmacol Ther 2001; 17: 131–149, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Iwamoto T, Morita T, Kanazawa T, et al. Effect of KB-2796, a new calcium antagonist, and other diphenylpiperazines on [3H]nitrendipine binding. Jpn J Pharmacol 1988; 48: 241–247, [PUBMED], [INFOTRIEVE], [CSA]
- Kanazawa T, Toda N. Inhibition by KB-2796, a new Ca2+ entry blocker, of the contractile response of isolated cerebral arteries in the dog. Folia Pharmacol Jpn 1987; 89: 365–373, [CSA]
- Kanazawa T, Nakasu Y, Matsuda M, Handa J. Acute effects of 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)-piperazine dihydrochloride, KB-2796, on cerebral blood flow in unanesthetized cats. Arch Jpn Chir 1986; 55: 682–688, [CSA]
- Yamada C, Harada K, Shimamoto A, et al. Effects of lomerizine on cerebral blood flow and systemic arterial blood pressure in anesthetized dogs. Jpn Pharmacol Ther 1997; 25: 797–802, [CSA]
- Akaike N, Ishibashi H, Hara H, et al. Effect of KB-2796, a new diphenylpiperazine Ca2+ antagonist, on voltage-dependent Ca2+ current and oxidative metabolism in dissociated mammalian CNS neurons. Brain Res 1993; 619: 263–270, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hara H, Yokota K, Shimazawa M, Sukamoto T. Effect of KB-2796, a new diphenylpiperazine Ca2+ antagonist, on glutamate-induced neurotoxicity in rat hippocampal primary cell cultures. Jpn J Pharmacol. 1993; 61: 361–365, [PUBMED], [INFOTRIEVE], [CSA]
- Hara H, Ozaki A, Yoshidomi M, Sukamoto T. Protective effect of KB-2796, a new calcium antagonist, in cerebral hypoxia and ischemia. Arch Int Pharmacodyn Ther 1990; 304: 206–218, [PUBMED], [INFOTRIEVE], [CSA]
- Levkovitch-Verbin H, Quigley H A, Martin K R, et al. A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest Ophthalmol Vis Sci 2003; 44(8)3388–3393, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Honjo M, Tanihara H, Kido N, et al. Expression of ciliary neurotrophic factor activated by retinal Muller cells in eyes with NMDA- and kainic acid-induced neuronal death. Invest Ophthalmol Vis Sci 2000; 41: 552–560, [PUBMED], [INFOTRIEVE], [CSA]
- Perry V H. Evidence for an amacrine cell system in the ganglion cell layer of the rat retina. Neuroscience. 1981; 6: 931–944, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Dreyer E B, Zurakowski D, Schumer R A, et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996; 114: 299–305, [PUBMED], [INFOTRIEVE], [CSA]
- Sucher N J, Lei S Z, Lipton S A. Calcium channel antagonists attenuate NMDA receptor-mediated neurotoxicity of retinal ganglion cells in culture. Brain Res. 1991; 551: 297–302, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Weiss J H, Hartley D M, Koh J, Choi D W. The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity. Science 1990; 247: 1474–1477, [PUBMED], [INFOTRIEVE], [CSA]
- Toriu N, Akaike A, Yasuyoshi H, et al. Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp Eye Res 2000; 70: 475–484, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schwartz M. Optic nerve crush: protection and regeneration. Brain Res Bull 2004; 62: 467–471, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yoles E, Muller S, Schwartz M. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. J Neurotrauma 1997; 14: 665–675, [PUBMED], [INFOTRIEVE], [CSA]
- Klocker N, Zerfowski M, Gellrich N C, Bahr M. Morphological and functional analysis of an incomplete CNS fiber tract lesion: graded crush of the rat optic nerve. J Neurosci Methods 2001; 110: 147–153, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sawada A, Neufeld A H. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp Eye Res 1999; 69: 525–531, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Selles-Navarro I, Villegas-Perez M P, Salvador-Silva M, et al. Retinal ganglion cell death after different transient periods of pressure-induced ischemia and survival intervals: a quantitative in vivo study. Invest Ophthalmol Vis Sci 1996; 37: 2002–2014, [PUBMED], [INFOTRIEVE], [CSA]
- Barres B A, Jacobson M D, Schmid R, et al. Does oligodendrocyte survival depend on axons?. Curr Biol 1993; 3(8)489–497, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Crowe M J, Bresnahan J C, Shuman S L, et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med. 1997; 3(1)73–76, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Levkovitch-Verbin H, Quigley H A, Kerrigan-Baumrind L A, et al. Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci 2001; 42(5)975–982, [PUBMED], [INFOTRIEVE], [CSA]
- Berkelaar M, Clarke D B, Wang Y C, et al. Axotomy results in delayed death and apoptosis of retinal ganglion cells in adult rats. J Neurosci 1994; 14(7)4368–4374, [PUBMED], [INFOTRIEVE], [CSA]
- Maxwell W L, Watt C, Graham D I, Gennarelli T A. Ultrastructural evidence of axonal shearing as a result of lateral acceleration of the head in non-human primates. Acta Neuropathol. 1993; 86: 136–144, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Maeda K, Sawada A, Matsubara M, et al. A novel neuroprotectant against retinal ganglion cell damage in a glaucoma model and an optic nerve crush model in the rat. Invest Ophthalmol Vis Sci 2004; 45: 851–856, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Moalem G, Monsonego A, Shani Y, et al. Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J 1999; 13: 1207–1217, [PUBMED], [INFOTRIEVE], [CSA]
- McKerracher L, Hirscheimer A. Slow transport of the cytoskeleton after axonal injury. J Neurobiol. 1992; 23: 568–578, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lafuente Lopez-Herrera M P, Mayor-Torroglosa S, Miralles de Imperial J, et al. Transient ischemia of the retina results in altered retrograde axoplasmic transport: neuroprotection with brimonidine. Exp Neurol 2002; 178: 243–258, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang L, Inoue M, Dong K, Yamamoto M. Retrograde axonal transport impairment of large-and medium-sized retinal ganglion cells in diabetic rat. Curr Eye Res. 2000; 20: 131–136, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Minckler D S, Bunt A H, Johanson G W. Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey. Invest Ophthalmol Vis Sci 1977; 16: 426–441, [PUBMED], [INFOTRIEVE], [CSA]
- Quigley H A, Addicks E M, Green W R, Maumenee A E. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol 1981; 99: 635–649, [PUBMED], [INFOTRIEVE], [CSA]
- Chan S Y, Ochs S, Worth R M. The requirement for calcium ions and the effect of other ions on axoplasmic transport in mammalian nerve. J Physiol. 1980; 301: 477–504, [PUBMED], [INFOTRIEVE], [CSA]
- Johansson J O. Influence of low IOP and low calcium on retrograde axoplasmic transport in rat optic nerve in vitro. Exp Eye Res 1985; 41: 739–744, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Taft W C, Clifton G L, Blair R E, De Lorenzo R J. Phenytoin protects against ischemia-produced neuronal cell death. Brain Res 1989; 483: 143–148, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Brady S T, Crothers S D, Nosal C, McClure W O. Fast axonal transport in the presence of high Ca2+: evidence that microtubules are not required. Proc Natl Acad Sci USA 1980; 77: 5909–5913, [PUBMED], [INFOTRIEVE], [CSA]
- Lees G J. Inhibition of the retrograde axonal transport of dopamine-beta-hydroxylase antibodies by the calcium ionophore A23187. Brain Res. 1985; 345: 62–67, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Osborne N N, Cazevielle C, Carvalho A L, et al. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res 1997; 751: 113–123, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Osborne N N, De Santis L, Bae J B, et al. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp Eye Res 1999; 69: 331–342, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Takahashi K, Lam T T, Edward D P, et al. Protective effects of flunarizine on ischemic injury in the rat retina. Arch Ophthalmol 1992; 110: 862–870, [PUBMED], [INFOTRIEVE], [CSA]
- Eschweiler G W, Bahr M. Flunarizine enhances rat retinal ganglion cell survival after axotomy. J Neurosci Sci. 1993; 116: 34–40, [CSA]